Correlations of O6‑methylguanine DNA methyltransferase (MGMT) promoter methylation status with magnetic resonance imaging texture features and prognosis of glioblastomas

Wang,Rujia; Sun,Zhengjun; Sun,Jinghua; Ma,Menhua; Wang,Haiping

doi:10.3892/mco.2024.2803

Correlations of O⁶‑methylguanine DNA methyltransferase (MGMT) promoter methylation status with magnetic resonance imaging texture features and prognosis of glioblastomas

Authors:
- Rujia Wang
- Zhengjun Sun
- Jinghua Sun
- Menhua Ma
- Haiping Wang
View Affiliations

Affiliations: Department of Radiology, Tangshan Gongren Hospital, Tangshan, Hebei 063000, P.R. China, Department of Radiology, Tangshan Gongren Hospital, Tangshan, Hebei 063000, P.R. China
Published online on: November 12, 2024 https://doi.org/10.3892/mco.2024.2803
Article Number: 8
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

O6‑methylguanine DNA methyltransferase (MGMT) promoter methylation is associated with the prognosis of patients with glioblastomas. With the aim of facilitating the discrimination of glioblastoma molecular phenotypes and improving the accuracy of molecular imaging diagnosis, the present retrospective study analyzed the association between MGMT promoter methylation and glioblastoma magnetic resonance imaging (MRI) texture features and prognosis. A total of 128 patients with pathologically diagnosed glioblastoma who had undergone preoperative MRI were enrolled. MRI texture features were extracted using 3D Slicer software and their relationship with MGMT promoter methylation was evaluated. In total, seven MRI texture features were significantly different between glioblastomas with methylated and unmethylated MGMT promoters‑energy, entropy, uniformity, autocorrelation, and variance in gray level co‑occurrence matrix, gray level non‑uniformity and cluster shade. Glioblastomas with methylated and unmethylated MGMT promoters differed in tumor location, with the former predominantly located in the temporal lobe [Model I, area under the curve (AUC): 0.697]. Among MRI texture features, variance was significantly different between methylation groups (Model II, AUC: 0.838). Significant overall survival (OS) differences were noticed between patients with methylated and unmethylated MGMT promoters, between patients with preoperative Karnofsky performance status (KPS) scores ≥80 and <80, and among patients with glioblastoma who received radiotherapy, chemotherapy, or concurrent chemoradiotherapy. The seven MRI texture features may serve as independent predictors of prognosis for patients with glioblastoma with methylated MGMT promoters. MRI texture features demonstrated improved and more accurate diagnostic performance than MRI features regarding MGMT promoter methylation status prediction. For patients with glioblastoma with preoperative KPS scores ≥80, those with methylated MGMT promoters had significantly longer OS. Concurrent chemoradiotherapy had a significantly improved prognosis than either radiotherapy or chemotherapy alone. In summary, the present study provided a non‑invasive, cost‑effective method for detecting MGMT promoter methylation and can significantly contribute to personalized treatment planning for patients with glioblastoma, potentially improving their quality of life.

View Figures

View References

1	Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P and Ellison DW: The 2016 world health organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 131:803–820. 2016.PubMed/NCBI View Article : Google Scholar
2	Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, et al: The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro-Oncology. 23:1231–1251. 2021.PubMed/NCBI View Article : Google Scholar
3	Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 17 (Suppl):iv1–iv62. 2015.PubMed/NCBI View Article : Google Scholar
4	Della Monica R, Cuomo M, Buonaiuto M, Costabile D, Franca RA, Del Basso De Caro M, Catapano G, Chiariotti L and Visconti R: MGMT and whole-genome DNA methylation impacts on diagnosis, prognosis and therapy of glioblastoma multiforme. Int J Mol Sci. 23(7148)2022.PubMed/NCBI View Article : Google Scholar
5	Teske N, Karschnia P, Weller J, Siller S, Dorostkar MM, Herms J, von Baumgarten L, Tonn JC and Thon N: Extent, pattern, and prognostic value of MGMT promotor methylation: Does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma? J Neurooncol. 156:317–327. 2022.PubMed/NCBI View Article : Google Scholar
6	Min TL, Allen JW, Velazquez Vega JE, Neill SG and Weinberg BD: MRI imaging characteristics of glioblastoma with concurrent gain of chromosomes 19 and 20. Tomography. 7:228–237. 2021.PubMed/NCBI View Article : Google Scholar
7	Pease M, Gersey ZC, Ak M, Elakkad A, Kotrotsou A, Zenkin S, Elshafeey N, Mamindla P, Kumar VA, Kumar AJ, et al: Pre-operative MRI radiomics model non-invasively predicts key genomic markers and survival in glioblastoma patients. J Neurooncol. 160:253–263. 2022.PubMed/NCBI View Article : Google Scholar
8	Zhang M, Chen HZ, Cui YY, Zhang ZZ and Ma XD: The associations between preoperative conventional MRI features and genetic biomarker status in newly diagnosed GBMs: A clinical summary and prognostic analysis. Turk Neurosurg. 31:880–887. 2021.PubMed/NCBI View Article : Google Scholar
9	Do DT, Yang MR, Lam LHT, Le NQK and Wu YW: Improving MGMT methylation status prediction of glioblastoma through optimizing radiomics features using genetic algorithm-based machine learning approach. Sci Rep. 12(13412)2022.PubMed/NCBI View Article : Google Scholar
10	Verduin M, Primakov S, Compter I, Woodruff HC, van Kuijk SMJ, Ramaekers BLT, te Dorsthorst M, Revenich EGM, ter Laan M, Pegge SAH, et al: Prognostic and predictive value of integrated qualitative and quantitative magnetic resonance imaging analysis in glioblastoma. Cancers (Basel). 13(722)2021.PubMed/NCBI View Article : Google Scholar
11	Safaei R, Mojtahedi H, Hanaei S, Razavi A, Esmaeili M, Sadr M, Rezaei A, Edalatfar M, Kashani HK, Sadeghi-Naini M, et al: MGMT gene rs1625649 polymorphism in Iranian patients with brain glioblastoma: A case control study. Avicenna J Med Biotechnol. 15:48–52. 2023.PubMed/NCBI View Article : Google Scholar
12	Kitange GJ, Mladek AC, Carlson BL, Schroeder MA, Pokorny JL, Cen L, Decker PA, Wu W, Lomberk GA, Gupta SK, et al: Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. Clin Cancer Res. 18:4070–4079. 2012.PubMed/NCBI View Article : Google Scholar
13	Blakstad H, Brekke J, Rahman MA, Arnesen VS, Miletic H, Brandal P, Lie SA, Chekenya M and Goplen D: Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions. PLoS One. 18(e0281166)2023.PubMed/NCBI View Article : Google Scholar
14	Kurdi M, Shafique Butt N, Baeesa S, Alghamdi B, Maghrabi Y, Bardeesi A, Saeedi R, Al-Sinani T, Alghanmi N, Bari MO, et al: The impact of IDH1 mutation and MGMT promoter methylation on recurrence-free interval in glioblastoma patients treated with radiotherapy and chemotherapeutic agents. Pathol Oncol Res. 27(1609778)2021.PubMed/NCBI View Article : Google Scholar
15	Haque W, Thong E, Andrabi S, Verma V, Butler BE and the BS: Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas. J Clin Neurosci. 85:115–121. 2021.PubMed/NCBI View Article : Google Scholar
16	Davnall F, Yip CS, Ljungqvist G, Selmi M, Ng F, Sanghera B, Ganeshan B, Miles KA, Cook GJ and Goh V: Assessment of tumor heterogeneity: An emerging imaging tool for clinical practice? Insights Imaging. 3:573–589. 2012.PubMed/NCBI View Article : Google Scholar
17	Ladenhauf VK, Galijasevic M, Kerschbaumer J, Freyschlag CF, Nowosielski M, Birkl-Toeglhofer AM, Haybaeck J, Gizewski ER, Mangesius S and Grams AE: Peritumoral ADC values correlate with the MGMT methylation status in patients with glioblastoma. Cancers (Basel). 15(1384)2023.PubMed/NCBI View Article : Google Scholar
18	Qureshi SA, Hussain L, Ibrar U, Alabdulkreem E, Nour MK, Alqahtani MS, Nafie FM, Mohamed A, Mohammed GP and Duong TQ: Radiogenomic classification for MGMT promoter methylation status using multi-omics fused feature space for least invasive diagnosis through mpMRI scans. Sci Rep. 13(3291)2023.PubMed/NCBI View Article : Google Scholar
19	Eccles SA and Welch DR: Metastasis: Recent discoveries and novel treatment strategies. Lancet. 369:1742–1757. 2007.PubMed/NCBI View Article : Google Scholar
20	Saxena S, Jena B, Mohapatra B, Gupta N, Kalra M, Scartozzi M, Saba L and Suri JS: Fused deep learning paradigm for the prediction of O6-methylguanine-DNA methyltransferase genotype in glioblastoma patients: A neuro-oncological investigation. Comput Biol Med. 153(106492)2023.PubMed/NCBI View Article : Google Scholar
21	Choi HJ, Choi SH, You SH, Yoo RE, Kang KM, Yun TJ, Kim JH, Sohn CH, Park CK and Park SH: MGMT promoter methylation status in initial and recurrent glioblastoma: Correlation study with DWI and DSC PWI features. AJNR Am J Neuroradiol. 42:853–860. 2021.PubMed/NCBI View Article : Google Scholar
22	Yaltirik CK, Yilmaz SG, Ozdogan S, Bilgin EY, Barut Z, Ture U and Isbir T: Determination of IDH1, IDH2, MGMT, TERT and ATRX gene mutations in glial tumors. In Vivo. 36:1694–1702. 2022.PubMed/NCBI View Article : Google Scholar
23	Ius T, Pignotti F, Della Pepa GM, Bagatto D, Isola M, Battistella C, Gaudino S, Pegolo E, Chiesa S, Arcicasa M, et al: Glioblastoma: From volumetric analysis to molecular predictors. J Neurosurg Sci. 66:173–186. 2022.PubMed/NCBI View Article : Google Scholar
24	Sanai N, Alvarez-Buylla A and Berger MS: Neural stem cells and the origin of gliomas. N Engl J Med. 353:811–822. 2005.PubMed/NCBI View Article : Google Scholar
25	Li HY, Sun CR, He M, Yin LC, Du HG and Zhang JM: Correlation between tumor location and clinical properties of glioblastomas in frontal and temporal lobes. World Neurosurg. 112:e407–e414. 2018.PubMed/NCBI View Article : Google Scholar
26	Drabycz S, Roldán G, Robles P, Adler D, Mcintyre J, Magliocco A, Cairncross JG and Mitchell JR: An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage. 49:1398–1405. 2010.PubMed/NCBI View Article : Google Scholar
27	Kickingereder P, Bonekamp D, Nowosielski M, Kratz A, Sill M, Burth S, Wick A, Eidel O, Schlemmer HP, Radbruch A, et al: Radiogenomics of glioblastoma: Machine learning-based classification of molecular characteristics by using multiparametric and multiregional MR imaging features. Radiology. 281:907–918. 2016.PubMed/NCBI View Article : Google Scholar
28	Egger J, Kapur T, Fedorov A, Pieper S, Miller JV, Veeraraghavan H, Freisleben B, Golby AJ, Nimsky C and Kikinis R: GBM volumetry using the 3D slicer medical image computing platform. Sci Rep. 3(1364)2013.PubMed/NCBI View Article : Google Scholar